NURO
NeuroMetrix, Inc.
Set alert
- YTD
- 0.00%
- 1 year
- 0.00%
- Open
- 4.36
- Prev close
- 4.58
- Mkt cap
- 8.07M
- Vol
- 35.59K
- Avg vol
- 21.57K
- EPS
- -4.51
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 4.33
- High
- 4.69
- Forward P/E
- 9.88
- Beta
- 2.30
- Short ratio
- 1.52
- Inst. own
- 3.01%
- Dividend
- 0.00
- Ex-div date
- Mar 27, 2007
- 50-d avg
- 4.05
- 200-d avg
- 3.91
- 1y target
- 0.00
Key statistics
- Market cap
- 8.07M
- Enterprise value
- -7.03M
- Trailing P/E
- 0.00
- Forward P/E
- 9.88
- PEG ratio
- 0.00
- Price / sales
- 2.14
- Price / book
- 0.49
- EPS (TTM)
- -4.51
- Beta
- 2.30
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -203.71%
- Revenue (TTM)
- 3.77M
- Revenue growth
- -51.20%
- Free cash flow
- 0
- Total cash
- 14.83M
- Total debt
- 0
- Return on equity
- -42.78%
- Shares outstanding
- 2.04M
- Short % of float
- 1.54%
- 50-day average
- 4.05
- 200-day average
- 3.91
Analyst view
Consensus: none
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 5, 2024 | Sep 1, 2024 | 0.00 | -0.75 | — | — |
| Aug 6, 2024 | Jun 1, 2024 | 0.00 | -0.74 | — | — |
| May 15, 2024 | Mar 1, 2024 | 0.00 | -1.67 | — | — |
| Feb 22, 2024 | Dec 1, 2023 | 0.00 | -1.43 | — | — |
| Oct 26, 2023 | Sep 1, 2023 | 0.00 | -1.68 | — | — |
| Jul 27, 2023 | Jun 1, 2023 | 0.00 | -1.52 | — | — |
About NeuroMetrix, Inc.
NeuroMetrix, Inc., a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use. The company offers its products to managed care organizations, endocrinologists, podiatrists, and primary care physicians; occupational health, primary care, internal medicine, orthopedic, and hand surgeons; and pain medicine physicians, neurologists, physical medicine and rehabilitation physicians, and neurosurgeons. NeuroMetrix, Inc. was founded in 1996 and is headquartered in Woburn, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- United States
- Website
- neurometrix.com
News
- electroCore Completes Acquisition of NeuroMetrix, Gaining Access to its Quell Platform, Creating Significant Player in Non-Invasive Bioelectronic Technologies
- NEUROMETRIX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of NeuroMetrix, Inc. - NURO
- SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of NeuroMetrix, Inc. - NURO
- NURO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of NeuroMetrix, Inc. Is Fair to Shareholders
- electroCore Enters Definitive Deal To Acquire NeuroMetrix, Including Its Quell Platform
- NeuroMetrix to be Acquired by electroCore
- electroCore to Acquire NeuroMetrix, Gaining Access to its Quell Platform and Positioning Itself as a Significant Player in Non-Invasive Bioelectronic Medicine and Wellness
- NeuroMetrix Q3 Loss Narrows Y/Y, Quell Sales Drives Growth
- NeuroMetrix Reiterates its Review of Strategic Alternatives
- NeuroMetrix, Inc. (NURO) Q2 2024 Earnings Call Transcript
Your note
Sign in to keep a note on NURO — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| FLUEGEL BRADLEY M | Director | Conversion of Exercise of derivative security | Apr 29, 2024 | 8,634 |
| GOODMAN DAVID E | Director | Conversion of Exercise of derivative security | Apr 29, 2024 | 7,602 |
| GOZANI SHAI N | Chief Executive Officer | Conversion of Exercise of derivative security | Oct 31, 2024 | 13,812 |
| HIGGINS THOMAS J | Chief Financial Officer | Conversion of Exercise of derivative security | Oct 31, 2024 | 10,633 |
| HIGGINS THOMAS T | Chief Financial Officer | Conversion of Exercise of derivative security | Feb 1, 2023 | 47,868 |
| HOROWITZ JOSHUA S | Director | Sale | Apr 21, 2024 | 83,938 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Mariner, LLC | 0.76% | 15,457 | 61.05K | Sep 29, 2024 |
| Vanguard Group Inc | 0.74% | 15,124 | 59.74K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.68% | 13,819 | 54.59K | Sep 29, 2024 |
| Osaic Holdings Inc | 0.42% | 8,560 | 33.81K | Sep 29, 2024 |
| Blackrock Inc. | 0.25% | 5,013 | 19.80K | Sep 29, 2024 |
| UBS Group AG | 0.07% | 1,458 | 5.76K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Extended Market Index Fund | 0.74% | 15,124 | 59.74K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.43% | 8,866 | 35.02K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.11% | 2,172 | 8.58K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.09% | 1,867 | 7.37K | Oct 30, 2024 |